0001209191-23-042984.txt : 20230720
0001209191-23-042984.hdr.sgml : 20230720
20230720210351
ACCESSION NUMBER: 0001209191-23-042984
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230720
FILED AS OF DATE: 20230720
DATE AS OF CHANGE: 20230720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FMR LLC
CENTRAL INDEX KEY: 0000315066
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41747
FILM NUMBER: 231100908
BUSINESS ADDRESS:
STREET 1: 245 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6175706339
MAIL ADDRESS:
STREET 1: 245 SUMMER STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER NAME:
FORMER CONFORMED NAME: FMR CORP
DATE OF NAME CHANGE: 19920717
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Turnstone Biologics Corp.
CENTRAL INDEX KEY: 0001764974
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 832909368
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 920 BROADWAY
STREET 2: 16TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 347-897-5988
MAIL ADDRESS:
STREET 1: 920 BROADWAY
STREET 2: 16TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2023-07-20
0
0001764974
Turnstone Biologics Corp.
TSBX
0000315066
FMR LLC
245 SUMMER STREET
BOSTON
MA
02210
0
0
1
1
See Remark 1
Series D Preferred Stock
Common Stock
91663
I
F-Prime Capital Partners Healthcare Fund V LP
Series C Preferred Stock
Common Stock
106496
I
F-Prime Capital Partners Healthcare Fund V LP
Series B-2 Preferred Stock
Common Stock
150809
I
F-Prime Capital Partners Healthcare Fund V LP
Series B-1 Preferred Stock
Common Stock
483684
I
F-Prime Capital Partners Healthcare Fund V LP
Series B-2 Preferred Stock
Common Stock
296396
I
Impresa Fund III Limited Partnership
Series B-2 Preferred Stock
Common Stock
4939
I
F-Prime Capital Partners Healthcare Advisors Fund V LP
The Series B-1, B-2, C, and D Preferred Shares are convertible on a 1-for-1 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date.
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110.
Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.
Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.
Stephanie J. Brown, Duly authorized under Powers of
Attorney, by and on behalf of FMR LLC and its direct
and indirect subsidiaries, and Abigail P. Johnson
2023-07-20